Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.65 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.65 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.65 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.65 |
| ▸ | CHRNG | P07510 | 1/20 | 0.52 |
| ▸ | CHRND | Q07001 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374508 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| SCHEMBL7374510 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| SCHEMBL155974 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| SCHEMBL8435282 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL7465854 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL7411186 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL8437416 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL7463132 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL8438541 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 | |
| Hydrochloric Acid SCHEMBL7463126 | 0.99 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | claimed |
| EP-2611788-B1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | UNIV FLORIDA (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2611788-B1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | UNIV FLORIDA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9440948-B2 | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440948-B2 | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-2611788-A2 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | University of Florida Research Foundation, Incorporated (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130157995-A1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-20 | — | — | US | disclosed |
| US-20130157995-A1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-20 | — | — | US | disclosed |
| WO-2012031220-A2 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157995-A1 | NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE | CHRNG, CHRNB1, CHRNB2 | CHRNB2 3/4885CHRNA4 11/4885CHRNA3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.